By Fineline Cube Merck & Co., Inc. (MSD; NYSE: MRK) and Gilead Sciences, Inc. (NASDAQ: GILD) announced today the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 clinical trial evaluating the combination of Trodelvy (sacituzumab govitecan) and KEYTRUDA (pembrolizumab) versus KEYTRUDA monotherapy in previously untreated metastatic non-small cell lung cancer (NSCLC) patients with PD-L1 tumor proportion score (TPS) ≥50%.
Clinical Trial Assessment
| Parameter | Outcome |
|---|---|
| Study Design | Phase 3, randomized, KEYNOTE-D46/EVOKE-03 |
| Patient Population | Treatment-naïve metastatic NSCLC with PD-L1 TPS ≥50% |
| Primary Endpoint | Progression-free survival (PFS) |
| Secondary Endpoint | Overall survival (OS) |
| PFS Result | Numerical improvement observed, but not statistically significant |
| OS Projection | Unlikely to achieve statistical significance at final analysis |
| Safety Profile | Consistent with known profiles of individual agents; no new safety signals |
Decision Framework
- Recommendation Source: External Data Monitoring Committee (eDMC)
- Data Reviewed: Pre-specified final analysis of PFS and interim analysis of OS
- Rationale: Low probability of achieving statistically significant OS benefit at planned final analysis
- Patient Impact: Participants will be notified and transitioned to appropriate alternative treatments per investigator discretion
Strategic Implications
- Pipeline Reprioritization: Both companies will redirect resources to other high-potential combination studies
- Trodelvy Development: Gilead continues to advance Trodelvy in other indications including HR+/HER2- breast cancer and urothelial cancer
- KEYTRUDA Combinations: Merck maintains active development of KEYTRUDA with multiple partners across diverse tumor types
- NSCLC Landscape: Monotherapy KEYTRUDA remains standard of care for first-line treatment in PD-L1 high (TPS ≥50%) metastatic NSCLC
Market Context
- NSCLC Treatment Paradigm: PD-L1 high metastatic NSCLC represents approximately 30% of all NSCLC cases
- Combination Therapy Trends: Despite strong rationale for ADC-immunotherapy combinations, clinical success has been limited by toxicity and efficacy challenges
- Competitive Environment: Multiple pharmaceutical companies continue to explore different ADC-IO combinations in various tumor types
- Investor Impact: The discontinuation is not expected to significantly impact near-term revenue projections for either company
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development decisions, pipeline priorities, and strategic implications. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market conditions.-Fineline Info & Tech